<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00891670</url>
  </required_header>
  <id_info>
    <org_study_id>GCS-0901-D</org_study_id>
    <nct_id>NCT00891670</nct_id>
  </id_info>
  <brief_title>Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism</brief_title>
  <acronym>ACCEL2C19</acronym>
  <official_title>Validation of Adjunctive Cilostazol According to CYP2C19 Polymorphism: Prospective, Randomized, Single-Center Trial:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the impact of adjunctive cilostazol on platelet
      inhibition in carriers and non-carriers of the loss-of-function CYP2C19 allele.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The additional platelet inhibition with clopidogrel, a thienopyridine inhibitor of the
      platelet P2Y12 adenosine diphosphate (ADP) receptor, has reduced the risk of ischemic events
      after coronary stent implantation. Because of inter-individual variability in platelet
      response to clopidogrel, a significant proportion of suboptimal platelet inhibition has been
      reported. In addition, persistent residual platelet reactivity measured with platelet
      function testing has shown the association with the cardiovascular outcomes after
      percutaneous coronary intervention(PCI).

      Various clinical factors and genetic polymorphisms have been studied to predict the degree of
      antiplatelet response to clopidogrel. Interestingly, recent studies found that carriers of
      the loss-of-function hepatic cytochrome (CYP) 2C19 allele had significantly lower levels of
      the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of
      major adverse cardiovascular events than did non-carriers, in the setting of PCI and acute
      coronary syndrome(ACS). These findings raise the need of solutions to overcome enhanced
      post-clopidogrel platelet reactivity by the influence of the loss-of-function CYP2C19 allele.
      Increasing the dose of clopidogrel and new potent P2Y12 antagonists(such as prasugrel) may be
      alternative antiplatelet regimens in patients with the loss-of-function CYP variant.

      Cilostazol reversibly induces platelet inhibition via its blockade of phosphodiesterase (PDE)
      type 3 and is catalysed mainly by CYP3A. A recent study demonstrated that adjunctive
      cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) intensified platelet
      inhibition as compared with a high maintenance-dose (MD) of 150 mg/day. Therefore, triple
      antiplatelet therapy could also be an alternative antiplatelet therapy to improve platelet
      inhibition and clinical outcomes in carriers of CYP2C19 mutant allele.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">July 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of maximal platelet aggregation</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of high post-clopidogrel platelet reactivity</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Maximal Platelet Aggregation</condition>
  <condition>Late Platelet Aggregation</condition>
  <condition>High Post-Treatment Platelet Reactivity</condition>
  <arm_group>
    <arm_group_label>triple group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received cilostazol 100 mg twice daily in addition to aspirin 100mg and clopidogrel 75mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high maintenance dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received clopidogrel 150 mg/day with aspirin 100mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>100mg twice daily for at least 1 month</description>
    <arm_group_label>triple group</arm_group_label>
    <other_name>pletaal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>75mg once daily (triple group arm)
150mg once daily (high maintenance dose group arm)</description>
    <arm_group_label>high maintenance dose group</arm_group_label>
    <other_name>plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>aspirin 100mg</description>
    <arm_group_label>triple group</arm_group_label>
    <arm_group_label>high maintenance dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be at least 18 years of age

          2. Significant coronary artery stenosis (&gt; 70% by visual estimate)

          3. Elective coronary stent implantation

        Exclusion Criteria:

          1. Acute myocardial infarction

          2. Hemodynamic instability active bleeding and bleeding diatheses

          3. Oral anticoagulation therapy with warfarin,use of peri-procedural glycoprotein
             IIb/IIIa inhibitors

          4. Contraindication to antiplatelet therapy

          5. Left ventricular ejection fraction &lt; 30%

          6. Leukocyte count &lt; 3,000/mm3, platelet count &lt; 100,000/mm3

          7. AST or ALT ≥ 3 times upper normal

          8. Serum creatinine level ≥ 2.5 mg/dL

          9. stroke within 3 months

         10. Noncardiac disease with a life expectancy &lt; 1 year

         11. Inability to follow the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Hoon Jeong, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeong-Sang Natinal University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Hoon Jeong, MD, phD</last_name>
    <phone>82-55-750-8065</phone>
    <email>goodoctor@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gyeong-Sang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <state>Gyeong-Nam</state>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Young-Hoon Jeong, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>April 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2009</study_first_posted>
  <last_update_submitted>April 30, 2009</last_update_submitted>
  <last_update_submitted_qc>April 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Young-Hoon Jeong</name_title>
    <organization>Gyeongsang National University Hospital</organization>
  </responsible_party>
  <keyword>CYP2C19 polymorphism</keyword>
  <keyword>platelet</keyword>
  <keyword>Adjunctive cilostazol</keyword>
  <keyword>high maintenance dose clopidogrel</keyword>
  <keyword>P2Y12 Reaction Unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

